{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T14:37:12.542627+00:00","company":{"ticker":"NVCT","cik":1875558,"company_name":"Nuvectis Pharma, Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"6942a71dddea88a5c108d25db8520f39b99d618d","cik":1875558,"ticker":"NVCT","company_name":"Nuvectis Pharma, Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":null},"claim":"Nuvectis Pharma, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 5, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-055264","anchor_url":"https://secwatch.observer/filing/0001104659-26-055264#claim-6942a71dddea88a5c108d25db8520f39b99d618d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/0001104659-26-055264-index.htm"},{"fact_type":"earnings_release","fact_key":"343ec6b0bded5a9f0804d645275b4cb513dff6c0","cik":1875558,"ticker":"NVCT","company_name":"Nuvectis Pharma, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$4.2 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":null},"claim":"Nuvectis Pharma, Inc. reported first quarter ended March 31, 2024 results: net income $4.2 million.","evidence_excerpt":"First Quarter 2024 Financial Results Cash, and cash equivalents were $19.5 million as of March 31, 2024, compared to $19.1 million as of December 31, 2023. The increase of $0.4 million in the cash balance in the first quarter of 2024 is a result of the utilization of the at-the-market facility, partially offset by the operating expenses for the quarter. The Company's net loss was $4.2 million for the three months ended March 31, 2024, compared to $4.0 million for the three months ended March 31, 2023, an increase in net loss of $0.2 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-057782","anchor_url":"https://secwatch.observer/filing/0001104659-24-057782#claim-343ec6b0bded5a9f0804d645275b4cb513dff6c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/0001104659-24-057782-index.htm"},{"fact_type":"earnings_release","fact_key":"67a2cf60ccec4aa7c7ad45b4c400d9aac7523312","cik":1875558,"ticker":"NVCT","company_name":"Nuvectis Pharma, Inc.","filed_at":"2024-03-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$22.3 million","period_text":"the fiscal year ended December 31, 2023","report_date":"2024-03-05","result_type":"reported_results","revenue_text":null},"claim":"Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2023 results: net income $22.3 million.","evidence_excerpt":"The Company's net loss was $22.3 million for the year ended December 31, 2023, compared to $19.1 million for the year ended December 31, 2022","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-030773","anchor_url":"https://secwatch.observer/filing/0001104659-24-030773#claim-67a2cf60ccec4aa7c7ad45b4c400d9aac7523312","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/0001104659-24-030773-index.htm"}]}